Research Ethics in Clinical Pharmacology Tens of thousands of clinical trials involving drugs are taking place each year. When the researchers are clinicians, they often recruit amongst their patients. Given […]
Introduction For the past two decades in Canada, patient groups funded by pharmaceutical companies have dominated public conversations about the effectiveness and safety of prescription drugs. These groups receive unrestricted […]
Adverse drug reactions (ADRs) are an important part of the process of determining the safety of drugs and treatments. Reports of ADRs by consumers has become a significant portion of the total yet only 1-5% of ADRs are ever reported. The consumer has the biggest stake in ensuring that ADRs are documented and that pharmaceutical manufacturers are held accountable for their mistakes.
One individual broke away from the standard Lipitor “solution” when he experienced continued side-effects from the treatment and began to follow a health alternative including changes in diet and lifestyle. His success is a living example that alternatives not only exist but are obtainable.
The overdiagnosis of diseases like cancer provides no life-saving benefit yet can greatly decrease the patients’ quality of life because of the side effects of the treatments and unjustified fear of a disease that does not threaten their lives.
Doctors accept information from Big Pharma at face value and ask patients to trust in the statistics they use to determine levels of risk for bone densit. However, they can fail to either appreciate a patient’s own research or their discomfort with the “facts” the doctor is using to inform that patient. Sara Denton shares her own experience.
Off-label prescribing, although legal for physicians in Canada, is illegal for pharmaceutical companies to promote and fines have been ineffective in preventing this practice. Many off-label prescriptions are for conditions difficult to test for, are aimed at women or children and can have serious adverse effects. Drug companies should be required to collect systematic scientific data on these drugs and medical products and seek market authorization for these uses.